The DOI matches its Crossref record; 235 of the 235 references it cites were found in a registry or an index; 53 of the 273 sources its claims cite were checked for support.
The roles of DNA, RNA and histone methylation in ageing and cancer
Open accessAbstract
Chromatin is a macromolecular complex predominantly comprising DNA, histone proteins and RNA. The methylation of chromatin components is highly conserved as it helps coordinate the regulation of gene expression, DNA repair and DNA replication. Dynamic changes in chromatin methylation are essential for cell-fate determination and development. Consequently, inherited or acquired mutations in the major factors that regulate the methylation of DNA, RNA and/or histones are commonly observed in developmental disorders, ageing and cancer. This has provided the impetus for the clinical development of epigenetic therapies aimed at resetting the methylation imbalance observed in these disorders. In this Review, we discuss the cellular functions of chromatin methylation and focus on how this fundamental biological process is corrupted in cancer. We discuss methylation-based cancer therapies and provide a perspective on the emerging data from early-phase clinical trial therapies that target regulators of DNA and histone methylation. We also highlight promising therapeutic strategies, including monitoring chromatin methylation for diagnostic purposes and combination epigenetic therapy strategies that may improve immune surveillance in cancer and increase the efficacy of conventional and targeted anticancer drugs.
Overview
CoChat Summary
TL;DR
This review discusses how DNA, RNA and histone methylation are dynamically regulated and dysregulated in ageing and cancer, and how mutations in methylation writers, readers and erasers, oncometabolites and oncohistones contribute to malignancy. It summarizes early clinical trial data for epigenetic therapies targeting DNA and histone methylation and argues that context-dependent biology will require rational combination strategies.
Key findings
- DNA methylation occurs at around 70% of CpG sites in mammalian genomes, except CpG islands in active promoters; ageing and cancer involve hypomethylation of repetitive elements and hypermethylation at promoter CpGs, polycomb targets and tumour suppressor genes.
- RNA methylation comprises over 70 known types, but biological functions remain largely unknown; m6A is dynamic and demethylatable, and D2HG inhibits FTO, leading to higher m6A levels in IDH1/2-mutant AML.
- Age-related clonal haematopoiesis (ARCH) occurs in more than 10% of adults aged 60 years or older; mutations in DNMT3A, TET2 and ASXL1 account for greater than 70% of ARCH cases and are associated with increased haematological malignancy risk and almost twofold increased cardiovascular mortality.
- Oncohistone H3K27M is found in up to 90% of diffuse intrinsic pontine gliomas, and around 30% of paediatric glioblastomas contain histone gene mutations; in trials, EZH2 inhibitor tazemetostat produced responses in 71% of follicular lymphoma patients with activating EZH2 mutations (11% complete response) versus 33% without EZH2 mutations (31% progressive disease), BAP1-inactivated mesothelioma showed 51% disease control at 12 weeks and 25% sustained to 24 weeks, DOT1L inhibitor pinometostat induced complete remission in 2 of 51 MLL-fusion leukaemia patients, LSD1 inhibitor ORY-1001 gave partial responses in 3 of 14 AML patients, and azacytidine response rates reached up to 60% in MDS.
Methods
- Design: narrative review; no primary experimental data are reported.
- Data/sample: published literature and early-phase clinical trial data on DNA, RNA and histone methylation in ageing and cancer, including a table of selected clinical trials.
- Main analysis: synthesis of methylation mechanisms, cancer-associated mutations and therapeutic strategies; no systematic review or meta-analysis is described.
Limitations
- Stated: preclinical models have significant limitations; genetically engineered mouse models fail to recapitulate intratumour heterogeneity, and patient-derived xenografts have major limitations in clonal representation and lack an effective immune system.
- Stated: preclinical evaluation of epigenetic compounds has not equated well with clinical success; many drugs showed remarkable preclinical promise but modest clinical efficacy, and mechanisms of resistance and the significance of non-histone substrates are not fully elucidated.
- Evident: as a narrative review, it lacks systematic search, quality assessment or meta-analysis and does not report primary data; conclusions rely on cited literature and selected trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 19 Not valid · 120 Not checked · 48 Own results and interpretations
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“and (ii) some methyltransferases methylating multiple classes of macromolecule 20 , as described above.”
What the sources say
- Could not verifycites [20] Jambhekar, A., Dhall, A. & Shi, Y. Roles and regulation of histone methylation in animal development. Nat. Rev. Mol. Cell Biol. https://doi.org/10.1038/s41580-019-0151-1 (2019). sourceExperimental — accuracy not yet measured
The Histone methylation regulators section says PRMT1 methylates histone and non-histone proteins, but both are proteins, not different classes of macromolecule. Searches for methyltransferases acting on both proteins and DNA or RNA found no passage in our copy establishing the attributed claim; page numbers were not available. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Furthermore, the ubiquitin-like domain within the ligase promotes ubiquitination of histone H3, which recruits DNMT1 to newly replicated chromatin to ensure the inheritance of DNA methylation 42 .”
What the sources say
- Could not verifycites [42] Pandolfini, L. et al. METTL1 promotes let-7 MicroRNA processing via m7G methylation. Mol. Cell. https://doi.org/10.1016/j.molcel.2019.03.040 (2019). sourceExperimental — accuracy not yet measured
The Introduction and Results discuss METTL1-mediated RNA methylation and let-7 processing, not the proposed UHRF1 mechanism. Searches for UHRF1, histone H3 ubiquitination, DNMT1, and newly replicated chromatin found no passage in our copy addressing the claim; no page numbers were provided. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Methylation such as H4K20me also underpins genomic integrity 34 .”
What the sources say
- Partly supportedcites [34] Kim, W., Choi, M. & Kim, J. E. The histone methyltransferase Dot1/DOT1L as a critical regulator of the cell cycle. Cell Cycle 13, 726–738 (2014). sourceExperimental — accuracy not yet measured
In the section 'Cell Cycle Checkpoint Following DNA Damage', our copy mentions H4K20 methylation only as a competing account of checkpoint-protein recruitment at double-strand breaks, reporting others' results: 'Botuyan et al. demonstrated that H4K20 methylation, not H3K79 methylation, is indispensable for the recruitment of mouse and human 53BP1', and in S. pombe Crb2 localization depends on H4K20 methylation (refs 109, 110). That covers the DNA-damage-response part of the claim, but the review's own statements about maintaining genomic integrity/stability are attributed to Dot1/DOT1L-dependent H3K79 methylation ('Dot1/DOT1L is required to maintain genomic stability following genotoxic stress'; 'required to maintain genomic stability without mutagenesis'), and H4K20 is otherwise only listed among SET-domain-methylated lysines in the Introduction. So the source supports H4K20me's role in 53BP1/Crb2 recruitment to damage sites, not the broader assertion that it underpins genomic integrity, and it credits that finding to Botuyan et al. (2006) and Sanders et al. (2004) rather than reporting it itself. (LLM, conf=0.70)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“Nevertheless, hypomethylation of these elements is observed in cancer cells 26,27 and this can lead to activation and transposition of the endogenous retroviral sequences thereby promoting genetic instability and tumour development 1 (Figure 2).”
What the sources say
- Not checked yetcites [26] Schubeler, D. Function and information content of DNA methylation. Nature 517, 321–326 (2015). source
- Could not verifycites [27] Maunakea, A. K., Chepelev, I., Cui, K. & Zhao, K. Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. Cell Res. 23, 1256–1269 (2013). sourceExperimental — accuracy not yet measured
The Results section on DNA methylation and RNA splicing reports that demethylation altered exon inclusion, including in HCT116 cells. Neither that passage nor the retrieved Discussion passage addresses activation or transposition of endogenous retroviral sequences, genetic instability, or tumour development. Searches for those terms and for hypomethylation of repetitive elements found no supporting passage in our copy. (LLM, conf=0.74)
- Not checked yetcites [1] Dawson, M. A. & Kouzarides, T. Cancer epigenetics: from mechanism to therapy. Cell 150, 12–27 (2012). source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“and increased levels of the heterochromatin-associated proteins, including histone H2A variant macroH2A (associated with gene repression 67 ) and HP1 β , were observed in tissues from old versus young mice and primates 68,69 .”
What the sources say
- Not checked yetcites [68] Sen, P., Shah, P. P., Nativio, R. & Berger, S. L. Epigenetic mechanisms of longevity and aging. Cell 166, 822–839 (2016). source
- Could not verifycites [69] McCauley, B. S. & Dang, W. Histone methylation and aging: lessons learned from model systems. Biochim. Biophys. Acta 1839, 1454–1462 (2014). sourceExperimental — accuracy not yet measured
Section 2 reports age-related changes in histone methylation in mice and macaques, but not increased levels of macroH2A or HP1β in old versus young tissues. Section 4.2 mentions HP1β only in the context of DNA-damage response. Searches for macroH2A and HP1β found no passage establishing the attributed comparison; page numbers were unavailable in our copy. (LLM, conf=0.75)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
104 more claims · 23 with their cited sources checked
Create a free account to see all 203 claims and to verify the 220 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 73
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, DNA and histone methylation landscapes change during aging, generally leading to global hypomethylation and promoter-specific hypermethylation (Michalak et al. 2019).”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as Michalak et al. 2019
Citations
Cites
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Self-citationA bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq
Dominissini, D., Moshitch-Moshkovitz, S., Schwartz, S., Salmon-Divon, M., Ungar, L., Osenberg, S., Cesarkas, K., Jacob-Hirsch, J., Amariglio, N., Kupiec, M., et al. (2012) · Nature · doi:10.1038/nature11112 · Cited by 4,884
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Genome-wide methylation profiles reveal quantitative views of human aging rates
Hannum, G., Guinney, J., Zhao, L., Zhang, L., Hughes, G., Sadda, S., Klotzle, B., Bibikova, M., Fan, J.-B., Gao, Y., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.10.016 · Cited by 4,270
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO
Jia, G., Fu, Y., Zhao, X., Dai, Q., Zheng, G., Yang, Y., Yi, C., Lindahl, T., Pan, T., Yang, Y.-G., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.687 · Cited by 4,106
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Dynamic RNA Modifications in Gene Expression Regulation
Roundtree, I. A., Evans, M. E., Pan, T., & He, C. (2017) · Cell · doi:10.1016/j.cell.2017.05.045 · Cited by 3,399
Research works printed but not linked: 3
- Zaccara, S., Ries, R. J. & Jaffrey, S. R. Reading, writing and erasing mRNA methylation. Nat. Rev. Mol. Cell Biol. In the press.
- Xhemalce, B., Dawson, M. A. & Bannister, A. J. in Epigenetic Regulation and Epigenomics (ed. Meyers, R. A.) 657–703 (Wiley-Blackwell, Weinheim, 2012).
- Biggar, K. K. & Li, S. S. C. Non-histone protein methylation as a regulator of cellular signalling and function. Nat. Rev. Mol. Cell Biol. 16, 5 (2014). · DOI · Paper page
Cited by
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
Xie, N., Zhang, L., Gao, W., Huang, C., Huber, P. E., Zhou, X., Li, C., Shen, G., & Zou, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00311-7 · Cited by 1,052
Kidney fibrosis: from mechanisms to therapeutic medicines
Huang, R., Fu, P., & Ma, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01379-7 · Cited by 781
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Benefits of Metformin in Attenuating the Hallmarks of Aging
Kulkarni, A. S., Gubbi, S., & Barzilai, N. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.001 · Cited by 766
Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer
Caliri, A. W., Tommasi, S., & Besaratinia, A. (2021) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2021.108365 · Cited by 681
Metadata
- Authors
- Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A.
- Affiliations
- The University of Melbourne (AU)
- University of Cambridge (GB)
- Corresponding author
- Bannister, Andrew J.
- Dawson, Mark A.
- Venue
- Nature Reviews Molecular Cell Biology
- Published
- 2019-07-03
- Volume
- 20
- Issue
- 10
- Pages
- 573-589
- ISSN
- 1471-0072 (ISSN-L)
- 1471-0080
- OpenAlex
- W2955248709
- Cited by
- 549
- References
- 235
- Citations by year
- 2026: 36 · 2025: 62 · 2024: 104 · 2023: 83 · 2022: 92 · 2021: 78 · 2020: 83 · 2019: 10
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Molecular Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- Cancer Research UK (17001, 20097)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Keywords
- chromatin methylation, DNA methylation, histone methylation, RNA methylation, aging, cancer, epigenetic therapy, DNA repair, gene expression regulation, tumor surveillance, clinical trials, cancer diagnosis
- MeSH terms
- DNA, Neoplasm, Histones, Neoplasm Proteins, Neoplasms, RNA Processing, Post-Transcriptional, RNA, Neoplasm, DNA Methylation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The roles of DNA, RNA and histone methylation in ageing and cancer. https://app.cochat.ai/papers/10.1038/s41580-019-0143-1
- The paper
- Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019). The roles of DNA, RNA and histone methylation in ageing and cancer. Nature Reviews Molecular Cell Biology. https://doi.org/10.1038/s41580-019-0143-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.